You might also like
Seer, Inc. is a life sciences company specializing in developing innovative products for deep molecular insights into the proteome, the complete set of proteins expressed by an organism. The company aims to advance biological research and understanding of diseases through its flagship Proteograph Product Suite, which enables scalable and unbiased proteomic analysis. Seer’s offerings are designed for research use and cater to laboratories seeking efficient and accessible proteomic workflows.
-
Product Revenue - Includes sales of the Proteograph SP100 instrument, consumable kits, and instrument upgrades, forming the core of Seer’s product offerings.
- Proteograph SP100 Instrument - A key component of the Proteograph Product Suite for proteomic analysis.
- Consumable Kits - Essential materials required for the Proteograph workflow.
- Instrument Upgrades - Enhancements to existing Proteograph instruments.
-
Related Party Revenue - Represents revenue from product and service sales to related parties, contributing significantly to the company’s operations.
-
Service Revenue - Comprises platform evaluations and other proteomic-related services offered to customers.
-
Grant and Other Revenue - Includes income from grant-funded activities, such as the Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Omid Farokhzad ExecutiveBoard | Chief Executive Officer, Chair | Board Member at Senti Biosciences; several privately held companies | Co-founder of Seer; led the development of the Proteograph Product Suite; former Professor at Harvard Medical School; co-founded multiple biotech companies. | View Report → |
David Horn Executive | President, Chief Financial Officer | None | Joined Seer as CFO in May 2020; became President in Nov 2023; previously Managing Director at Morgan Stanley in the Global Healthcare Group. | |
David Hallal Board | Lead Independent Director | CEO and Chairman of ElevateBio; Chairman of AlloVir, Scholar Rock, iTeos | Extensive leadership in biotech; former CEO of Alexion Pharmaceuticals; joined Seer’s board in 2018; appointed Lead Independent Director in 2020. | |
Deep Nishar Board | Director | Board Member at Dynamics Special Purpose Corp., Vir Biotechnology | Managing Director at General Catalyst; former Senior Managing Partner at SoftBank; extensive experience in technology and investment in life sciences. | |
Meeta Gulyani Board | Director, Chair of Audit Committee | Member of Novo Advisory Group | Joined Seer’s board in 2021; appointed Chair of Audit Committee in Dec 2023; former EVP at Merck KGaA; extensive experience in life sciences strategy and business development. | |
Nicolas Roelofs Board | Lead Independent Director | Chairman of Sengenics; Board Member of Velsera, LGC Group; Advisory Board Member of 908 Devices | Former President of Life Sciences Group at Agilent Technologies; extensive operational and advisory experience in life sciences tools and diagnostics industries. | |
Robert Langer Board | Director | Board Member at Moderna, Puretech Health, Frequency Therapeutics, Abpro Bio | Institute Professor at MIT; co-founder of Moderna; extensive experience in biotech innovation; serves on multiple public and private company boards. | |
Terrance McGuire Board | Director | Founding Partner of Polaris Partners; Board Member at Invivyd, Alector, Cyclerion | Co-founder of Polaris Partners; extensive experience in venture capital; serves on multiple boards in the biotech and healthcare sectors. |
-
Given that total revenue for Q3 2024 decreased by 3% year-over-year to $4 million, primarily due to a decrease in related party revenue and grant revenue , what strategies are you implementing to drive revenue growth and reverse this trend?
-
With a free cash flow loss of approximately $39 million for the nine months ended September 30, 2024, and expectations that the 2024 free cash flow loss will be less than in 2023 , what specific measures are you taking to reduce cash burn and move towards profitability?
-
In light of the continuing challenges in the capital purchasing environment causing elongated sales cycles for new instrumentation , how do you plan to accelerate the adoption of the Proteograph Product Suite and mitigate these macroeconomic headwinds?
-
Considering the increasing competition in the proteomics space with other solutions emerging to address similar challenges as the Proteograph , how does Seer plan to maintain its competitive edge and differentiate its offerings in this evolving market?
-
Regarding the recent partnership with Thermo Fisher Scientific to co-market and sell the Proteograph Product Suite starting in early 2025 , can you elaborate on how this collaboration is expected to impact your market reach and contribute to top-line growth in the coming year?
| Customer | Relationship | Segment | Details |
|---|---|---|---|
PrognomiQ, Inc. | Purchase agreements for products or services | All | 2023: 28% of total revenue (= $4.68M out of $16.7M) ; 2022: 32% of total revenue (= $4.96M out of $15.5M). |
No recent press releases or 8-K filings found for SEER.